SecBot SecBot
8-K ·Filed Feb 24, 2026

MBOT

Microbot Medical Inc.
NEUTRAL
Impact 3/10
Horizonmonths Processed8mo ago SEC0001493152-26-007900
8-K Item 1.01 + 5.02 (likely routine officer/director compensation agreement)
Actionable Insight • Neutral

Monitor future 10-Q filings for disclosure of the full financial impact of these compensation changes on operating expenses. No immediate trading action is warranted as this is routine executive compensation disclosure.

DirectionNeutral
Confidencehigh
Horizonmonths
Final — all horizons settled through T+60d
MBOT ▼ -32.82% at T+60d
NEUTRAL call -32.82% · α vs SPY -39.77% · entry $2.59 → $1.74
Entry = T+0 close
Feb 24, 2026
via day close
T+1d
-1.16%
call -1.16% · α -0.61%
$2.56
settled 8mo ago
T+5d
-5.41%
call -5.41% · α -4.31%
$2.45
settled 8mo ago
T+20d
-2.32%
call -2.32% · α +2.92%
$2.53
settled 7mo ago
T+60d
-32.82%
call -32.82% · α -39.77%
$1.74
settled 5mo ago

Price Chart

Loading chart...

Executive Summary

Microbot Medical Inc. (MBOT) filed an 8-K to disclose compensation adjustments for three executive officers and a special bonus for its CEO. The changes include salary and bonus increases for the CTO, CFO, and CMO, and a $140,000 special bonus for the CEO. These are routine personnel and compensation updates with no material financial impact.

Key Facts

  • Increased CTO Simon Sharon's annual base salary to NIS 1,008,000 and maximum bonus to 50% of base salary
  • Increased CFO Rachel Vaknin's annual base salary to NIS 756,000 and maximum bonus to 50% of base salary
  • Increased CMO Juan Diaz-Cartelle's maximum annual bonus to 50% of base salary
  • Authorized a special $140,000 bonus for CEO Harel Gadot
  • All changes are effective for the 2026 fiscal year

Financial Impact

Approximately $140,000 disclosed for CEO bonus; other compensation changes in NIS not converted to USD in filing

operating_expensesgeneral_and_administrative_expenses

Risk Factors

  • Potential for increased operating expenses from higher executive compensation
  • Currency risk from NIS-denominated salaries given the company is US-based

Market Snapshot

Exchange
Nasdaq

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001493152-26-007900
Exhibit: ex10-2.htm0001493152-26-007900
Exhibit: ex10-1.htm0001493152-26-007900
Exhibit: ex10-3.htm0001493152-26-007900
Document: 0001493152-26-007900-index-headers.html0001493152-26-007900
Document: 0001493152-26-007900-index.html0001493152-26-007900
Document: 0001493152-26-007900.txt0001493152-26-007900
22 reports for MBOT
Performance horizon
33% Hit rate @ T+1 2 of 6 directional calls Went positive at some point 4 of 6 best @ T+5▲ +9.39%May 26, 2026
Filters
Rows
Reports for MBOT — sortable, filterable
TypeNow
Oct 23, 2026
3d ago
8-K
NEUTRAL ★ 2/10
$0.9739 $0.9417▼ −3.31%▼ −4.02%$0.9417 (−3.31%)
Oct 20, 2026
6d ago
8-K
NEUTRAL ★ 3/10
$0.9475 $0.9401▼ −0.78%▼ −1.31%$0.9417 (−0.61%)
Oct 6, 2026
20d ago
8-K
NEUTRAL ★ 3/10
$1.07 $1.12▲ +4.67%▲ +4.91%$0.9417 (−11.99%)
Oct 6, 2026
20d ago
Press Release
NEUTRAL ★ 4/10
$1.07 $1.12▲ +4.67%▲ +4.91%$0.9417 (−11.99%)
Sep 28, 2026
28d ago
8-K
NEUTRAL ★ 3/10
$1.25 $1.25▼ −0.40%▼ −0.22%$0.9417 (−24.66%)
Aug 11, 2026
10w ago
8-K
BULLISH ★ 5/10
$1.68 $1.74▲ +3.27%▲ +3.02%$0.9417 (−43.95%)
Jul 21, 2026
13w ago
8-K
NEUTRAL ★ 2/10
$1.80 $1.77▼ −1.67%▼ −1.55%$0.9417 (−47.68%)
Jul 7, 2026
15w ago
8-K
BULLISH ★ 5/10
$1.90 $1.87▼ −1.58%▼ −1.27%$0.9417 (−50.44%)
Jun 30, 2026
16w ago
8-K
BULLISH ★ 5/10
$1.95 $1.91▼ −2.05%▼ −1.92%$0.9417 (−51.71%)
Jun 16, 2026
18w ago
8-K
NEUTRAL ★ 4/10
$1.82 $1.88▲ +3.30%▲ +4.55%$0.9417 (−48.26%)
Showing 10 of 22

US Market Status

Market Closed — Opens Tue (< 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Feb 24, 2026